About Pragya Pandey
Pragya is an equity research analyst and financial journalist with a passion for investing. In college she majored in finance and is currently pursuing the CFA program and is a Level II candidate.
When analyzing stocks, Pragya takes a fundamental approach and focuses on measuring a company's intrinsic value. Her goal is to help retail investors create successful portfolios to achieve financial success.
Recent Articles By Pragya Pandey
1 Robust Retail Stock to Consider Buying Despite Rising Prices
Despite rising prices, Chico’s FAS (CHS) reported solid financial results in the last quarterly release surpassing analysts’ earnings and revenue projections. In addition, given its higher-than-industry profitability and impressive growth attributes, we think the stock could be a great buy now. Read on to learn more...
Is UnitedHealth a Buy Following Its Strong Earnings Boost?
The shares of UnitedHealth (UNH) have garnered significant investor attention after it reported solid earnings in the latest quarterly release and raised its guidance for the upcoming months. So, let’s evaluate if it is worth buying the stock now. Read on...
Why This 1 Fast Food Restaurant Stock Is Worth Investing in
Shares of Nathan’s Famous (NATH) have gained significant investor attention lately based on its impressive quarterly and fiscal 2022 earnings results. In addition, the company’s robust profitability should further boost investors’ confidence in its prospects. So, let’s discuss in detail why it could be wise to add NATH to your portfolio. Read on to learn more...
1 Stock That Is Not Worth Chasing in 2022
As demand for vegan alternatives for meat-based products grows, Beyond Meat’s (BYND) innovative business model has enabled them to grab the market. However, the company’s lack of profitability and lofty valuation has raised significant investor concerns over its prospects. In addition, poor analysts’ ratings further make the stock’s near-term prospects look gloomy. So, we think the stock is best avoided now. Read on...
2 Value Stocks Every Investor Will Want to Look at This Summer
Concerns over aggressive interest rate rises to confront multi-decade high inflation, and the risk of an economic recession have all contributed to recent market volatility, leading the stocks of some high-quality companies to trade at attractive valuations. So, we believe fundamentally good value stocks Adam Resources & Energy (AE) and AutoNation (AN) could be a great addition to your watchlist now. Read on…
1 Biotech Stock That Stands out From the Rest
Amgen (AMGN) has undertaken several strategic growth initiatives to capitalize on the expanding biotech industry. In addition, several FDA drug approvals and other research and development breakthroughs make it well-positioned to witness significant growth in the near term, making it an ideal candidate for investors seeking to gain exposure in the biotech industry. Read on to learn more...
Is This Health Care Stock Still a Good Play 1 Year After Its IPO?
Doximity Inc. (DOC) made its stock market debut on June 25, 2021. However, the stock has lost 19.2% over the past year. So, let’s evaluate if it is worth buying the stock now…
Do This Stock's Strong Q2 Earnings Make It a Buy Right Now?
Global jeanswear leader Levi Strauss (LEVI) reported strong second-quarter earnings results and reiterated its guidance for the full year 2022. However, given its slightly higher-than-industry valuation, will it be wise to scoop up its shares now? Read on to learn our view…
Oracle Considering $1B in Cuts, Is the Stock Still a Buy?
Oracle (ORCL) recently announced its plans to lay off thousands of employees and cut costs by $1 billion. However, given that the company has been making several strategic advances to boost its cloud infrastructure platform is it worth buying the stock now? Let’s find out…